Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Kelowna, British Columbia, Canada
-
Surrey, British Columbia, Canada
-
Victoria, British Columbia, Canada
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
-
Kentville, Nova Scotia, Canada
-
-
Ontario
-
Barrie, Ontario, Canada
-
Burlington, Ontario, Canada
-
Kingston, Ontario, Canada
-
Kitchener, Ontario, Canada
-
Newmarket, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Homewood, Alabama, United States
-
-
Alaska
-
Anchorage, Alaska, United States
-
-
California
-
San Bernardino, California, United States
-
San Carlos, California, United States
-
San Diego, California, United States
-
Torrance, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
Longmont, Colorado, United States
-
Wheat Ridge, Colorado, United States
-
-
Connecticut
-
Newington, Connecticut, United States
-
Norwalk, Connecticut, United States
-
-
Florida
-
Celebration, Florida, United States
-
Longwood, Florida, United States
-
Plantation, Florida, United States
-
Tampa, Florida, United States
-
Trinity, Florida, United States
-
Venice, Florida, United States
-
Weston, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Centralia, Illinois, United States
-
Evanston, Illinois, United States
-
Peoria, Illinois, United States
-
-
Indiana
-
Jeffersonville, Indiana, United States
-
-
Michigan
-
Dearborn, Michigan, United States
-
Grand Rapids, Michigan, United States
-
Kalamazoo, Michigan, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Nevada
-
Henderson, Nevada, United States
-
-
New Jersey
-
West Orange, New Jersey, United States
-
-
New York
-
Albany, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Concord, North Carolina, United States
-
Winston Salem, North Carolina, United States
-
-
Ohio
-
Lima, Ohio, United States
-
-
Oklahoma
-
Ponca City, Oklahoma, United States
-
Tulsa, Oklahoma, United States
-
-
Oregon
-
Medford, Oregon, United States
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Arlington, Texas, United States
-
Austin, Texas, United States
-
Carrollton, Texas, United States
-
Fort Worth, Texas, United States
-
San Antonio, Texas, United States
-
-
Utah
-
Ogden, Utah, United States
-
Salt Lake City, Utah, United States
-
-
Virginia
-
Richmond, Virginia, United States
-
-
Washington
-
Mountlake Terrace, Washington, United States
-
Seattle, Washington, United States
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must have a total score of 8 or greater on the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and a score of > 0 on each of the 4 questions on the ICSI
- must have experienced bladder pain, urinary urgency and urinary frequency, each not related to a urinary tract infection, for at least 6 months prior to entry into the study
- must have averaged >= 10 voids per day (>=30 voids over 3 consecutive days) and averaged >= 1 void at night
- urine culture showing no evidence of urinary tract infection
- urine cytology showing no evidence of neoplastic cells
Exclusion Criteria:
- Scheduled for or use of intravesical therapy (eg, bladder distention, dimethyl sulfoxide) during or within 4 weeks prior to the study
- patients who have had cytoscopic evaluation within 4 weeks prior to the study
- patients who are currently (within last month) receiving other medications that may affect symptoms of interstitial cystitis (ie, antidepressants, antihistamines, antispasmodics, anticholinergics)
- patients who are chronic users of Schedule II narcotics or who are using any scheduled narcotics at the time of study entry
- patients taking coumadin, anticoagulants, heparin, or thrombolytic agents such as tissue plasminogen activator and streptokinase
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pentosan polysulfate sodium 100 mg once a day
One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
|
One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
|
|
Experimental: Pentosan polysulfate sodium 100 mg three times a day
One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
|
One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
|
|
Placebo Comparator: Placebo
Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks
|
One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Responders Defined as Having at Least a 30% Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint
Time Frame: Baseline to Week 24
|
The ICSI is a four-item self-administered instrument developed for the evaluation and management of patients with interstitial cystitis.
The index measures the presence and extent of symptoms including urinary urgency, urinary frequency, nocturia and pain/burning in the bladder.
Each question in the ICSI is on a 0-5 scale, where each answer is given a specific rating.
The sum of the individual question ratings is the score for the ICSI.
The range of the test is a score of 0 to 20.
A lower score indicates a better condition.
|
Baseline to Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Responders Defined as Having at Least a Four Point Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint
Time Frame: Baseline to Week 24
|
The ICSI is a four-item self-administered instrument developed for the evaluation and management of patients with interstitial cystitis.
The index measures the presence and extent of symptoms including urinary urgency, urinary frequency, nocturia and pain/burning in the bladder.
Each question in the ICSI is on a 0-5 scale, where each answer is given a specific rating.
The sum of the individual question ratings is the score for the ICSI.
The range of the test is a score of 0 to 20.
A lower score indicates a better condition.
|
Baseline to Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR004576
- C-2002-036 (Other Identifier: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.